EUVIMEDEUVIMED entdecken
Multizentrische Studie

Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study

M Hupé, A Streichenberger, P Wils, N Arab, M Serrero, A Amiot, A Bozon, L Vuitton, M Fumery, R Altwegg, M Nachury, X Hébuterne und 6 weitere

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.01.181 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von M Hupé und 17 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Grenoble Alpes/Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes/Institute for Advanced Biosciences, CNRS UMR 5309-…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Infliximab, Gastrointestinal Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. AIMS: To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous (SC) anti-TNF agent. METHODS: In this multicenter retrospective study (8 centers), we included all consecutive UC patients with prior exposure to subcutaneous anti-TNF, starting infliximab for symptomatic UC, excluding acute severe colitis. Corticosteroid-free clinical remission (CFREM) was assessed at week 14 (W14) and W52 while endoscopic improvement (CFREM + endoscopic Mayo score≤1) was evaluated at W14. RESULTS: Overall, 104 patients were included (pancolitis=54.8%, primary failure to subcutaneous anti-TNF=57.4%, concomitant immunosuppressant=53.8%, median partial Mayo score at baseline=7[5-8]). The rate of CFREM was 33.6% (35/104) at W14 and 40.4% (42/104) at W52. At W14, endoscopic improvement was achieved in 29.8%(31/104). In multivariable analysis, concomitant immunosuppressant was associated with higher rate of CFREM at W14(OR=2.83[1.06-7.54], p = 0.037) and W52(OR=2.68[1.16-6.22];p = 0.021), while primary failure to a previous subcutaneous anti-TNF agent led to lower rate of CFREM at W14 (OR=0.37[0.14-0.98], p = 0.046). After a median follow-up of 20.9 months[11.7-33.7]), 50.0%(52/104) patients had discontinued infliximab. CONCLUSION: Infliximab is an effective option in UC patients previously exposed to prior subcutaneous anti-TNF agent and should be used with concomitant immunosuppressant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInfliximabGastrointestinal AgentsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedInjections, SubcutaneousTreatment OutcomeRemission InductionTumor Necrosis Factor-alphaMultivariate AnalysisImmunosuppressive Agents

Stichwörter der Autor:innen

Bio-exposed patientsInflammatory bowel diseaseInfliximabReal-world dataSecond-line treatmentUlcerative colitis

Substanzen

InfliximabGastrointestinal AgentsTumor Necrosis Factor-alphaImmunosuppressive Agents

Autor:innen und Institutionen

  • Univ. Grenoble Alpes/Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes/Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France.
  • Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
  • Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France.
  • Gastro-entérologie et Nutrition Clinique, CHU de Nice, Université Côte d'Azur, Nice, France.
  • Department of Gastroenterology, University Hospital of Marseille Nord, Aix-Marseille, Marseille University, Marseille, France.
  • EC2M3-EA7375, Department of Gastroenterology, Groupe Hospitalier Henri Mondor-Albert Chennevier, Assistance Publique-Hôpitaux de Paris, University of Paris Est Créteil, Créteil, France.

Förderung

  • AbbVie

Zitieren

APA

Hupé, M., Streichenberger, A., Wils, P., Arab, N., Serrero, M., Amiot, A., Bozon, A., Vuitton, L., Fumery, M., Altwegg, R., Nachury, M., Hébuterne, X., Yzet, C., Coban, D., Dodel, M., Bazoge, M., Pereira, B., & Buisson, A. (2024). Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.01.181

Vancouver

Hupé M, Streichenberger A, Wils P, Arab N, Serrero M, Amiot A, et al. Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.01.181

BibTeX
@article{Hup2024,
  author = {Hupé, M and Streichenberger, A and Wils, P and Arab, N and Serrero, M and Amiot, A and Bozon, A and Vuitton, L and Fumery, M and Altwegg, R and Nachury, M and Hébuterne, X and Yzet, C and Coban, D and Dodel, M and Bazoge, M and Pereira, B and Buisson, A},
  title = {Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.01.181}
}
Kostenlos starten →